Ozempic Price in India (2026): What Each Dose Costs, and Why the Brand Costs More
The molecule is now commodity-cheap in India. So what is the branded price tag actually buying you?
ALTRcare Medical Team
Clinical Editorial
In the US, a month of branded semaglutide can cost over ₹85,000. In India, branded Ozempic or Wegovy costs ₹5,660 to ₹16,400 a month depending on dose, and Mounjaro ₹13,125 to ₹25,781 (October 2026 MRP). And as of 2026, generic semaglutide from Indian manufacturers sells for as little as ₹1,300 to ₹4,000 a month. Same active molecule. The price gap is enormous. So what are you actually paying for?
Updated 8 October 2026
Prices on this page were re-checked in October 2026. Novo Nordisk's April 2026 cut still holds (Ozempic and Wegovy from ₹5,660 a month), Mounjaro's MRP is unchanged, and generic semaglutide now makes up 82% of semaglutide units sold in India. A September 2026 review in Diabetes Care found typical monthly prices fell from ₹11,000 to ₹16,409 before the patent expiry to ₹2,000 to ₹3,500 after it.
Ozempic and Wegovy price by dose
| Dose | Ozempic | Wegovy |
|---|---|---|
| 0.25 mg | ₹5,660 | ₹5,660 |
| 0.5 mg | ₹8,100 | ₹8,100 |
| 1 mg | ₹9,100 | ₹9,100 |
| 1.7 mg | Not sold | ₹12,750 |
| 2.4 mg | Not sold | ₹16,400 |
At the starting doses Ozempic and Wegovy cost the same, because they are the same semaglutide in different pens. Your doctor raises the dose step by step, so the monthly bill rises in the first few months.
The molecule is now cheap
Semaglutide's patent expired in India on 20 March 2026, and domestic drugmakers moved fast: by May 2026 there were 35 semaglutide brands from 17 companies on sale, at a fraction of branded prices. The chemistry inside a ₹16,000 branded semaglutide pen (Wegovy at its higher doses) and a ₹1,500 generic vial is, for practical purposes, the same drug.
| Option | Typical monthly cost | What you get |
|---|---|---|
| Generic semaglutide (Indian manufacturers) | ₹1,300 – ₹4,000 | The molecule only. No screening, titration plan, or side-effect support. |
| Ozempic / Wegovy (branded semaglutide) | ₹5,660 – ₹16,400 | Same molecule, plus the auto-injector device and brand premium. |
| Mounjaro (tirzepatide) | ₹13,125 (2.5 mg) – ₹25,781 (15 mg) | A different, stronger molecule (dual GIP/GLP-1), still under patent in India. |
| Doctor-led programme on generic semaglutide | From about ₹3,500 | The generic molecule plus eligibility screening, correct titration, monitoring, and nutrition support. |
So why the markup?
A branded pen bundles three things: the molecule, a slick auto-injector device, and years of global marketing and brand premium. The device is genuinely convenient. The brand is not medicine. For most patients, a large share of the branded price is paying for everything except the thing that makes you lose weight.
But a cheap molecule isn't safe weight loss
Here's the catch the price tag hides. Semaglutide isn't paracetamol. It needs the right starting dose, a careful titration schedule, screening before you begin, and someone managing side effects when they hit. Buying the cheapest vial off a pharmacy shelf and self-dosing is exactly how people end up nauseated, dehydrated, and quitting in week two, convinced the drug failed them, when really the plan did.
What you should actually pay for
The smart spend in 2026 isn't the brand on the pen; it's the doctor behind the protocol. A proper programme covers eligibility screening (especially important for Indians with a normal BMI but high visceral fat), the right molecule and dose, titration, side-effect management, and the nutrition support that prevents muscle loss.
That's how ALTRcare is built: the affordable generic molecule, plus the medical supervision that the cheap-vial route skips. You're not paying a brand tax, you're paying for it to be done safely. And if a calorie deficit alone has failed you, there may be a hormonal reason worth checking first.
Frequently asked questions
How much does Ozempic cost in India?
Branded semaglutide pens (Ozempic and Wegovy) cost ₹5,660 a month at 0.25 mg, ₹8,100 at 0.5 mg and ₹9,100 at 1 mg, with Wegovy reaching ₹12,750 at 1.7 mg and ₹16,400 at 2.4 mg (prices effective April 2026, unchanged in October). Generic injectable semaglutide from Indian manufacturers starts far lower, from around ₹1,300–₹4,000 a month for the molecule alone. Generic prices vary by brand and pen or vial, so treat those as ranges rather than quotes.
Is generic semaglutide as good as branded Ozempic or Wegovy?
The active molecule is the same. The differences are in the delivery device, brand, and, most importantly, whether you have medical supervision around dosing and side effects.
How much does semaglutide cost per month in India in 2026?
Branded Ozempic and Wegovy run ₹5,660 to ₹16,400 a month depending on dose (Mounjaro, a different molecule, ₹13,125 to ₹25,781), while generic injectable semaglutide from Indian manufacturers can start around ₹1,300–₹4,000 a month for the molecule alone.
Why does a doctor-led programme cost more than the cheapest vial?
Because it includes the parts that make treatment work safely: screening, correct titration, side-effect management, and nutrition support to protect muscle. The cheapest vial includes none of that.
Is there a cheaper alternative to Ozempic in India?
Yes. Since the semaglutide patent expired on 20 March 2026, dozens of DCGI-approved generic semaglutide brands have launched (35 brands from 17 companies by May 2026), with pens from about ₹1,800 a month and vials from about ₹1,300. It is the same molecule as Ozempic and Wegovy.
Is Ozempic the same price as Wegovy in India?
At the 0.25, 0.5 and 1 mg doses, yes: both cost ₹5,660, ₹8,100 and ₹9,100 a month since Novo Nordisk's April 2026 price change. Only Wegovy is sold at the higher 1.7 mg (₹12,750) and 2.4 mg (₹16,400) doses.
Sources
- Novo Nordisk India sets price of Rs 202/day for starting dose of Ozempic and Wegovy (Indian Pharma Post, 31 March 2026)
- Ozempic price list (PharmEasy, 21 August 2026)
- Mounjaro price list (PharmEasy, 21 August 2026)
- Rs 325 to 4,200 a month: Dr Reddy's, Sun Pharma, Glenmark kick off generic semaglutide price war (ThePrint, 21 March 2026)
- India's GLP-1 market nears Rs 2,000 crore as semaglutide boom slows (Medical Dialogues, 21 June 2026)
- Generic competition slashes semaglutide prices after patent expiry (South First, 24 September 2026)
- Anti-obesity market stabilises as semaglutide generics plateau (BioSpectrum India, 11 July 2026)
- CDSCO approves Wegovy for adults living with fatty liver disease in India (BioSpectrum India, 18 July 2026)
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed, with no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
